Novavax vaccine 89% effective in clinical trial

Clinical trials of Novavax’s Covid-19 vaccine showed an 89.3 percent efficacy, the U.S. biotech company said in a release Thursday showing the results of phase 3 trials involving more than 15,000 people.

“NVX-CoV2373 has the potential to play an important role in solving this global public health crisis,” said company CEO Stanley Erck.

But the positive news was offset by the joint announcement that the vaccine is far less effective against the variant first identified in South Africa, which scientists believe is more contagious.

Leave a comment

Your email address will not be published. Required fields are marked *